NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date and time:** Wednesday 12 January 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Dr Lindsay Smith (Vice Chair) Items 4.1.3 to 4.2.2
3. James Avery Present for all items
4. Martin Bradley Present for all items
5. Dr Matthew Bradley Present for all items
6. Professor Sofia Dias Present for all items
7. Professor Rachel Elliott Present for all items
8. Chris Herring Present for all items
9. Dr Andrew Hitchings Present for all items
10. Dr Robert Hodgson Present for all items
11. Dr Bernard Khoo Present for all items
12. Ivan Koychev Present for all items
13. Dr Soo Fon Lim Present for all items
14. Dr Guy Makin Present for all items
15. Professor David Meads Present for all items
16. Giles Monnickendam Present for all items
17. Malcolm Oswald Present for all items
18. Dr Rebecca Payne Present for all items
19. Carole Pitkeathley Present for all items
20. Baljit Singh Present for all items
21. Professor John Watkins Present for all items

NICE staff present

Linda Landells, Associate Director Present for all items

Charlie Hewitt, Health Technology Assessment Adviser Present for all items

Luke Cowie, Health Technology Assessment Analyst Present for all items

Emily Eaton Turner, Technical Adviser, Commercial Risk Assessment, Present for all items

Ella Livingstone, Technical Adviser, Commercial Risk Assessment, Present for all items

Catrin Austin, Technical Analyst. Methods and Economics Team, Present for all items

Maroulla Whiteley, Business Analyst, RIA Present for all items

Korin Knight, Senior Medical Editor Present for all items

Mandy Tonkinson, Patient Involvement Advisor, PIP Items 1 to 4.1.3

Catherine Pank, Assistant Project Manager, COT Present for all items

Lyn Davies, Coordinator, MIP Items 1 to 4.1.3

Gemma Smith, Coordinator, COT Present for all items

Celia Mayers, Administrator, TA Present for all items

External assessment group representatives present

Nigel Armstrong, Kleijnen Systematic Reviews Ltd Items 1 to 4.1.3

Stephen Rice, Kleijnen Systematic Reviews Ltd Items 1 to 4.1.3

Clinical experts present

Prof. Peter Clark, CDF Clinical lead, NHS England Present for all items

Dr Alastair Greystoke, Consultant Medical Oncologist & Honorary Senior Lecturer, Clinical expert nominated by Royal College of Physicians, Items 1 to 4.1.3

Dr Thomas Newsom-Davis, Consultant Medical Oncologist, Clinical expert nominated by British Thoracic Oncology Group, Items 1 to 4.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Dr Megan John welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted committee member apologies.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 15 December 2021.

### Appraisal of tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations [ID3761]

* 1. Part 1 – Open session
		1. The chair welcomed the invited clinical experts, the National Clinical lead for Cancer drugs fund, external assessment group representatives, members of the public and company representatives from Merck Serono Ltd.
		2. The chair asked all committee members, clinical experts, the National Clinical lead for Cancer drugs fund, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared financial interests as the university of Leeds has received funding from BMS, Celgene and Sanofi for research in an un-related area. It was agreed his declaration would not prevent Professor Meads from participating in discussions on this appraisal.
* Committee member Dr Ed Wilson declared financial conflicts as BMS, Celgene, Consilient Health, MSD, Pfizer, and Roche are or have been clients of the company he works for, he confirmed they have worked on atezolizumab (Roche) but not in issues directly related to a technology appraisal. It was felt this may be perceived as a conflict. It was agreed that Dr Wilson would not attend discussions on this appraisal.
* Nominated clinical expert Dr Thomas Newsom-Davis declared financial interests as he has received support to attend educational conferences from AstraZeneca, BMS, Boehringer Ingelheim, Lilly, MSD, Otsuka, Roche and Takeda, advisory board fees from Amgen, Bayer, AstraZeneca, BMS, Boehringer Ingelheim, Eli-Lilly, Janssen, Merck, MSD, Novartis, Otsuka, Pfizer, Roche, Sanofi, and Takeda. and speaker bureau fees from AstraZeneca, Guardant, MSD, Roche, and Takeda. It was agreed his declarations would not prevent Dr Newsom-Davis from providing expert advice to committee.
* Nominated clinical expert Dr Alastair Greystoke declared financial interests as he has received consultancy and speaker fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, MSD, Novartis, Pfizer, and Roche. Dr Greystoke confirmed that although Pfizer and Novartis have unlicensed competitors in this indication. Work done was outside of this indication, he is also clinical lead for cancer for the NEY Genomic Laboratory Hub responsible for genomic testing in his region and a member of the Genomics Test Evaluation Working Group (Cancer). It was agreed his declarations would not prevent Dr Greystoke from providing expert advice to committee.
* No further conflicts of interest were declared for this appraisal.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Bernard Khoo, Professor Sofia Dias and Carole Pitkeathley.
	1. Part 2 – Closed session (company representatives, clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance or Final Draft Guidance (FDG). The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Draft Guidance or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10630>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 10 February 2022 and will start promptly at 09.30.